secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001728117-24-000057
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib
--------------------------------------------------------------------------------

- Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.
- Pro forma cash, cash equivalents and marketable securities $396M as of March 31, 2024.
- PROSERA Phase 3 PAH study topline results expected Q4 2025; registrational Phase 3 PH-ILD to start mid-2025.
- Net loss $41.9M ($0.19 per share) for Q1 2024 vs $49.2M ($0.52 per share) in Q1 2023.
- R&D expenses $32.4M in Q1 2024 down from $37.8M YoY, primarily due to terminated programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/0001728117-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/goss-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001728117-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer